Loading clinical trials...
Loading clinical trials...
In previous retrospective study (SEIFEM 2016 study) the investigators evaluated the incidence of proven/probable invasive aspergillosis (IA) and the role of mold active primary antifungal prophylaxis ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
University of Rome Tor Vergata
NCT03717623 · Posaconazole, Pharmacokinetics, and more
NCT06583512 · Invasive Aspergillosis, Antifungal Therapy
NCT04486885 · Cerebral Aspergillosis, Invasive Aspergillosis
NCT06028451 · Invasive Aspergillosis
NCT01614145 · Focus: Immunocompromised Individuals at High Risk of Aqcuiring Invasive Aspergillosis
Tor Vergata University
Roma, RM
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions